On the other hand, adding bevacizumab to sorafenib had nearly no effect on sorafenib’s IC50 following a 48 h treatment period with an unexpected increase in sorafenib IC50 following the 24 h treatment period. Treatment of HepG2/C3A cancer cell line with bevacizumab 5 ng/mL and 100 μg/mL for 48 h was previously reported to increase telomerase activity which in turn resulted in the overexpression of VEGFR1 and VEGFR254. Here, FLT1 is linked to cancer.